Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
13 citing papers in PubMed, 15 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors at 7 institutions in 2 countries.
Brianna J Klein *Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO, USA.
Anagha Deshpande *Tumor Initiation and Maintenance Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Khan L CoxDepartment of Physics, Ohio State University, Columbus, OH, USA.
Fan XuanCenter for Epigenetics, Van Andel Research Institute, Grand Rapids, MI, USA.ORCID 0000-0002-8070-3309
Mohamad ZandianDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0002-4967-6867
Karina BarbosaTumor Initiation and Maintenance Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0000-0002-6233-3332
Sujita KhanalTumor Initiation and Maintenance Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Qiong TongDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO, USA.
Yi ZhangDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0001-8170-9983
Pan ZhangTumor Initiation and Maintenance Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Amit SinhaBasepair Inc, New York, NY, USA.
Stefan K BohlanderLeukaemia and Blood Cancer Research Unit, Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand.ORCID 0000-0002-2202-9088
Xiaobing ShiCenter for Epigenetics, Van Andel Research Institute, Grand Rapids, MI, USA.ORCID 0000-0001-5242-8189
Hong WenCenter for Epigenetics, Van Andel Research Institute, Grand Rapids, MI, USA.ORCID 0000-0001-8739-4572
Michael G PoirierDepartment of Physics, Ohio State University, Columbus, OH, USA.
Aniruddha J DeshpandeTumor Initiation and Maintenance Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA. adeshpande@sbpdiscovery.org.ORCID 0000-0002-5240-9356
Tatiana G KutateladzeDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO, USA. tatiana.kutateladze@cuanschutz.edu.ORCID 0000-0001-7375-6990
Sanford Burnham Prebys Medical Discovery Institute · USUniversity of Colorado Denver · USVan Andel Institute · USThe Ohio State University · USAltair Engineering (United States) · USUniversity of Auckland · NZUniversity of Colorado Anschutz Medical Campus · US
Funding
Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael Jackson · 1985 to 2026
$107.2M
Targeting acetylated histone H4 by MLL4R01AG067664 · NIA · UNIVERSITY OF COLORADO DENVER · PI KUTATELADZE, TATIANA G · 2021 to 2025
$2.1M
Molecular analysis of ASH1LR01CA252707 · NCI · UNIVERSITY OF COLORADO DENVER · PI TATIANA G KUTATELADZE · 2020 to 2026
$1.9M
Dissecting functional cooperation among subunits in a catalytic ribonucleoproteinR01GM120582 · NIGMS · OHIO STATE UNIVERSITY · PI GOPALAN, VENKAT · 2016 to 2019
$1.9M
The role of JADE in HBO complexesR01HL151334 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI KUTATELADZE, TATIANA G · 2020 to 2023
$1.8M
Epigenetic mechanisms for regulation of p300R01GM135671 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI KUTATELADZE, TATIANA G · 2020 to 2023
$1.4M
Understanding how two related mammalian histone acetyl transferase co-activators, SAGA and ATAC, differentially regulate chromatin dynamics and transcriptionR01GM131626 · NIGMS · OHIO STATE UNIVERSITY · PI POIRIER, MICHAEL GUY · 2019 to 2021
$1.3M
Interdomain crosstalk in MORC3R01GM125195 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI KUTATELADZE, TATIANA G · 2017 to 2021
$1.3M
Regulatory Mechanisms of Linker Histones and Their Post-Translational ModificationsR01GM121966 · NIGMS · OHIO STATE UNIVERSITY · PI POIRIER, MICHAEL GUY · 2017 to 2020
$1.2M
The role of AF10 in normal and leukemic hematopoiesisR00CA154880 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI DESHPANDE, ANIRUDDHA J. · 2015 to 2017
$747k
Targeting acetylated histone H4 by MLL4R56AG067664 · NIA · UNIVERSITY OF COLORADO DENVER · PI KUTATELADZE, TATIANA G · 2020 to 2020
$512k
The role of AF10 in normal and leukemic hematopoiesisK99CA154880 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DESHPANDE, ANIRUDDHA J. · 2011 to 2012
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The role of the PZP domain of AF10 in acute leukemia driven by AF10 translocations. · full record | OpenQuestion